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Multiple transforming growth factor (TGF)-b–induced
fibrogenic signals have been described in vitro. To evaluate
mechanisms in vivo, we used an adriamycin nephropathy
model in 129x1/Svj mice that display massive proteinuria
by days 5 to 7 and pathological findings similar to human
focal segmental glomerulosclerosis by day 14. TGF-b mRNA
expression increased after day 7 along with nuclear
translocation of the TGF-b receptor–specific transcription
factor Smad3. Inhibiting TGF-b prevented both pathological
changes and type-I collagen and fibronectin mRNA
expression, but proteinuria persisted. Renal Akt was
phosphorylated in adriamycin-treated mice, suggesting PI3-
kinase activation. Expression of mRNA for the p110c isozyme
of PI3-kinase was specifically increased and p110c colocalized
with nephrin by immunohistochemistry early in disease.
Nephrin levels subsequently decreased. Inhibition of p110c
by AS605240 preserved nephrin expression and prevented
proteinuria. In cultured podocytes, adriamycin stimulated
p110c expression. AS605240, but not a TGF-b receptor kinase
inhibitor, prevented adriamycin-induced cytoskeletal
disorganization and apoptosis, supporting a role for p110c
in podocyte injury. AS605240, at a dose that decreased
proteinuria, prevented renal collagen mRNA expression
in vivo but did not affect TGF-b-stimulated collagen induction
in vitro. Thus, PI3-kinase p110c mediates initial podocyte
injury and proteinuria, both of which precede
TGF-b-mediated glomerular scarring.
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Renal fibrosis is a complex process involving multiple cell
types and a broad variety of mediators. Podocyte injury is
one of the initial steps in the sequence leading to glomer-
ulosclerosis and subsequent renal scarring.1,2 Misdirected
attempts at tissue repair then involve numerous other
cells in scar formation.3 Multiple studies have implicated
transforming growth factor (TGF)-b as a pivotal cytokine
that promotes both physiological healing and pathological
scarring, including in the kidney.4–7 We previously showed
that TGF-b activates type-I collagen expression in cultured
kidney mesangial and epithelial cells via a complex signaling
mechanism in which the classical TGF-b/Smad pathway is
regulated by a number of non-canonical pathways involving
ERK MAP kinase,8 phosphatidylinositol-3-kinase (PI3K),9
protein kinase Cd,10 and the Rho-family GTPases.11,12 In
diabetes, TGF-b has been shown to interact with PI3K to
promote mesangial cell dysfunction.13,14 TGF-b-PI3K cross
talk also was demonstrated to be important in renal
epithelial-to-mesenchymal transition in vitro and in vivo.15
The present study was aimed at elucidating the involve-
ment of TGF-b and PI3K in an animal model of acquired
kidney fibrosis. Adriamycin (ADR)-induced kidney damage
is one of the few existing murine models of acquired
glomerulonephropathy,16 in which progressive renal changes
lead to terminal renal failure.17 By a mechanism that is not
completely understood, ADR induces pathological glomeru-
lar changes that are similar to human focal segmental
glomerular sclerosis.18 TGF-b involvement in the ADR model
has been suggested in earlier studies.5,19 Some of the model’s
limitations include severity of the kidney injury and strain
specificity—mostly restricted to Balb/c mice.20 A genome-
wide search linked strain susceptibility to anthracyclines to a
specific genetic locus, which is shared between Balb/c and
129/SvJ, but not with C57BL6 mice.21,22 Accordingly, we
extended the ADR model to the 129x1/SvJ strain and
observed that ADR indeed induces similar, but milder,
pathological changes than were seen in Balb/C strain of mice.
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We implicate TGF-b and the p110g isoform of PI3K in the
pathogenesis of this nephropathy model. Our data suggest
that PI3K p110g promotes podocyte injury resulting in
proteinuria, via cell signaling that is not directly dependent
on TGF-b/Smad3 pathway activation. Conversely, TGF-b/
Smad3 signaling is not involved in proteinuria, but instead
has a significant part in consequent fibrogenesis. Our results
define mechanisms underlying proteinuria and fibrogenesis
in chronic kidney disease and indicate that these mechanisms
are likely to be distinct.
RESULTS
Characterization of ADR nephropathy in 129x1/Svj mice
Three to five days following tail-vein administration of one
dose of ADR (15mg/kg body weight) to 129x1/Svj mice,
albuminuria developed and progressed to massive proteinuria
and hypoalbuminemia during the second and third weeks of
disease (Figure 1a and b). In addition, ADR-treated mice
manifested hypercholesterolemia (Figure 1b and Table 1).
Renal function was mild initially, primarily with blood urea
nitrogen elevation, but progressed to advanced kidney
dysfunction with doubling of baseline serum creatinine about
4 weeks after ADR (Figure 1b). By light microscopy, kidneys of
ADR-treated mice showed glomerular mesangial hypercellu-
larity and extracellular matrix expansion accompanied by
partially collapsed glomerular capillary loops. Two weeks
following ADR administration, some of the glomeruli had
segmental sclerosis/hyalinosis, whereas others showed prolif-
eration of parietal epithelial cells reminiscent of cellular
crescents. Global glomerular sclerosis with hyalinization of the
entire glomerular tuft was observed as well. Influx of inflam-
matory cells into the interstitium, accompanied by interstitial
edema, was also seen. Tubular atrophy followed, beginning at
week 2 (Figure 1c) and progressing thereafter (not shown). At
2 weeks, mRNA expression of fibronectin and type-I collagen
in kidneys of ADR-treated mice increased up to 15-fold
(Figure 2a). At the same time, an increased amount of
connective tissue in the glomerular and tubular compartments
was observed, as assessed by trichrome staining (Figure 2b, top
panels). This was associated with increased type-I collagen
expression, as demonstrated by immunohistochemistry
(Figure 2b, bottom panels).
TGF-b mediates fibrogenesis in mouse ADR nephropathy
By using cell culture systems, we and others previously
showed that TGF-b is an important mediator of renal
fibrosis. Here, we examined TGF-b involvement in our model
of acquired kidney fibrosis. Consistent with previous
reports,5,19 TGF-b1 mRNA levels were increased in ADR
kidneys, peaking around the third week after the injurious
stimulus and subsiding gradually thereafter (Figure 3a). The
downstream mediator of TGF-b, Smad3, was phosphorylated
and accumulated in nuclei of kidney tubular and glomerular
cells in ADR-treated mice (Figure 3b), indicating that Smad3
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Figure 1 |Adriamycin (ADR) nephropathy in 129x1/Svj mice. Eight-week-old mice received a single injection of ADR (15mg/kg body
weight) or control (saline) via tail vein. (a) At the indicated time, urine was collected for albumin determination. Proteinuria peaked at 14–21
days (Po0.001 by two-way analysis of variance comparing control vs. ADR, *Po0.05 compared with control by Fisher’s post-hoc analyses,
N¼ 2–4 at each time point). (b) At the time of killing, blood was collected for albumin, cholesterol, creatinine, and blood urea nitrogen (BUN)
determination. The dotted horizontal lines show normal serum levels, as determined by results from control mice. The mice showed
decreased albumin and increased cholesterol at 14–28 days. BUN and creatinine were mildly elevated at 14 days but increased further at 28
days. Statistical summary at the 2-week point is shown in Table 1. (c) Kidney samples (day 14) were sectioned and stained using periodic
acid–Schiff and photographed at a lens objective of  10 or  40. Bars¼ 100mm and 25mm, respectively. ADR mice showed focal
glomerulosclerosis, crescent formation, tubular atrophy, and proteinaceous material in the tubular lumen.
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is activated. To test whether TGF-b mediates fibrosis in this
model, a soluble TGF-b type-II receptor-Fc (sTbRII-Fc) was
used. This chimeric protein has previously been shown to
inhibit renal fibrosis in mouse diabetes.23 sTbRII-Fc decreased
glomerulomegaly, glomerulosclerosis, and crescent formation
in ADR-treated mouse kidneys (Figure 4a and Table 2).
Table 1 | Nephrotic indices and kidney function of 129/SvJ mice 2 weeks after ADR administration
Albumin (g/dl) Cholesterol (mg/dl) BUN (mg/dl) Creatinine (mg/dl)
Control (N) 2.8±0.77 (31) 153±26 (26) 37.9±14.3 (31) 0.25±0.07 (31)
ADR (N) 2.17±0.83 (29) 410±228 (28) 51.5±30.7 (29) 0.27±0.11 (25)
P value 0.004 o0.001 0.036 0.499
Abbreviations: ADR, adriamycin; BUN, blood urea nitrogen.
40
Type-I collagen
35
30
25
ADR
Cont
20
20
18
16
14
12
10
8
6
4
2
Ty
pe
-I 
co
lla
ge
n
Tr
ic
hr
om
e
Control ADR
×10
×40
×40 oil
15
10
5
0
0
0 7 14 21 28
0 7 14 21 28
Days
Fibronectin
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Figure 2 | Extracellular matrix accumulation in mouse adriamycin (ADR) nephropathy. (a) mRNA analysis by quantitative PCR shows
increased fibronectin and type-I collagen by 14 days (N¼ 2–4 at each time point. Statistical analyses for data at 2 weeks are shown in Figures
4b and 7a). (b) Trichrome staining (upper panels) shows increased glomerular and tubulointerstitial accumulation of extracellular matrix.
Specific staining using anti-collagen I antibody shows that type-I collagen accumulates in the glomerulus and the tubulointerstitium (bottom
panels). Mice were killed at day 14 after ADR administration. Bars¼ 100mm ( 10 objective) and 25mm ( 40 oil objective). Cont, control.
14
12
10
ADR
ADR
×40 oil
(Ig
G)
pS
m
ad
3Control
Control
8
6
4
2
0
0 7 14 21 28
Days
Fo
ld
 c
ha
ng
e
TGF-β1
Figure 3 | Transforming growth factor (TGF)-b activity in the adriamycin (ADR)-treated mouse kidneys. (a) Quantitative PCR shows an
increase in mRNA for TGF-b1 mRNA beginning at 14 days and reaching a maximum at 21 days (N¼ 2–4 at each time point. Statistical
analyses of results at 2 weeks are shown in Figures 4b and 9b). (b) Staining of tissue sections for phospho-Smad3 (Ser 425) shows a marked
increase in nuclear staining in a kidney section from an ADR-treated mouse (day 14). Nuclear translocation of Smad3 is a hallmark of Smad3
activation. Bar¼ 25mm. IgG, immunoglobulin G.
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Induction of type-I collagen, fibronectin, and TGF-b1 mRNA
after ADR administration was also attenuated by sTbRII-Fc
(Figure 4b). Interestingly, albuminuria persisted, despite the
improved glomerular fibrotic changes, with the sTbRII-Fc
treatment (Figure 5a). Further, loss of podocyte markers
caused by ADR, as determined by podocalyxin mRNA
expression (Figure 5b) and by nephrin staining (Figure 5c),
was not prevented by sTbRII-Fc. These results suggest that
TGF-b mediates glomerular fibrosis but not podocyte injury
and subsequent proteinuria in our model. Successful inhibi-
tion of the TGF-b/Smad pathway by the sTbRII-Fc was
confirmed by reduction of Smad3 phosphorylation in the
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Figure 4 | Soluble type-II transforming growth factor (TGF)-b receptor (sTbRII-Fc) ameliorates fibrotic changes in adriamycin (ADR)
nephropathy. ADR nephropathy was induced as described for Figure 1, and the treatment group additionally received sTbRII-Fc, 4mg/kg
via tail vein the day before ADR injection and twice a week intraperitoneally (2mg/kg) until the end of the experiment at day 14.
(a) Representative sections stained with periodic acid–Schiff. Inhibition of TGF-b signaling improved the histological outcome of the disease.
Bars¼ 25 mm ( 40 oil objective) and 100mm ( 10 objective). (b) sTbRII-Fc ameliorated type-I collagen (COL1A1), fibronectin, and TGF-b1
mRNA expression induced by ADR (N shown in parentheses under each condition. COL1A1: P¼ 0.019 by one-way analysis of variance
(ANOVA), *P¼ 0.005 compared with control, wP¼ 0.0085 compared with ADR; Fibronectin: Po0.001 by one-way ANOVA, *Po0.001
compared with control, wP¼ 0.0046 compared with ADR; TGF-b1: Po0.001 by one-way ANOVA, *P¼ 0.003 compared with control,
wP¼ 0.029 compared with ADR. ‘ ’ represents outliers.
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treated mouse kidneys (Figure 5d). Efficacy of the sTbRII-Fc
was also confirmed in cultured human kidney epithelial cells
(HKC) by inhibition of TGF-b-induced COL1A1 mRNA
(data not shown).
PI3K isoform p110c has a role in ADR nephropathy
Previous work in our laboratory showed that PI3K activity is
required for TGF-b-stimulated type-I collagen production in
mesangial cells in culture.9 We therefore examined the role of
PI3K in our mouse model of acquired nephropathy. PI3K
activity, as determined by staining for phosphorylation of the
downstream target protein Akt, was detectable in the ADR-
treated mouse kidneys, in glomeruli and to a lesser extent in
tubules (Figure 6a). Levels of mRNAwere comparable for the
most commonly described PI3K catalytic subunits, the
ubiquitous isoforms a and b, as well as for their regulatory
subunits. In contrast, the p110g catalytic subunit isoform was
specifically upregulated in the ADR kidney (Figure 6b). This
finding was at first surprising to us, as the p110g isoform is
particularly highly expressed in lymphoid cells, with low to
modest expression in other organs.24 To test whether the
upregulation of p110g mRNA in the ADR kidney reflects
its expression by kidney cells, rather than by infiltrating
inflammatory cells, kidney sections were stained for p110g,
along with nephrin as a podocyte marker. p110g staining was
weakly positive in glomeruli of control mouse kidney, and
became more obvious at days 3 and 6 after ADR adminis-
tration (Figure 6c). The p110g staining colocalized with
nephrin, suggesting p110g expression in podocytes. It is
noteworthy that disruption of nephrin staining starts as early
as day 3 after the ADR administration. The timing of
podocyte marker loss and p110g expression coincides with
the onset of albuminuria, but precedes overt fibrotic changes.
To further assess a potential role for PI3Kg in ADR
nephropathy, we administered a specific inhibitor of p110g,
AS605240,25 30mg/kg body weight intraperitoneally 1 day
before ADR administration, followed by injection every other
day. No significant animal, tissue, or cell toxicity related to the
Table 2 | Semiquantitative scale of histological changes in
129/SvJ model of acquired nephropathy
Glomeruli Control ADR ADR+sTbRII
Mesangial hypercelluarity 0 3 0
Mesangial matrix expansion 0 2 0
Parietal cell hyperplasia 0 3 1
Focal sclerosis 0 Yes 0
Global sclerosis 0 Yes 0
Tubules
Intraluminal casts 0 3 2
Tubular atrophy 0 1–2 1
Interstitium
Inflammatory infiltrate 0 3 1
Abbreviation: ADR, adriamycin.
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Figure 5 |Podocyte damage and proteinuria are not mediated by transforming growth factor (TGF)-b. (a) Soluble TGF-b type-II
receptor-Fc (sTbRII-Fc) did not decrease proteinuria (day 14; N shown in parentheses for each condition, P¼ 0.0016 by one-way analysis of
variance (ANOVA), *P¼ 0.0026, wP¼ 0.004 compared with control). (b) sTbRII-Fc did not prevent an adriamycin (ADR)-stimulated decrease in
podocalyxin mRNA expression (day 14; N shown in parentheses for each condition, P¼ 0.0016 by one-way ANOVA, *P¼ 0.0026, wP¼ 0.004
compared with control). (c) Nephrin staining was decreased at day 14 of the ADR administration even with the sTbRII-Fc treatment. 40 1.4
(oil) objective. Bar¼ 20mm. (d) Smad3 phosphorylation, determined by densitometrical analyses of immunoblotting, was decreased by
sTbRII-Fc, confirming the efficacy of the inhibitory treatment in vivo (day 14; N shown in parentheses for each condition, P¼ 0.0032 by one-
way ANOVA, *P¼ 0.0024 compared with control, wP¼ 0.027 compared with ADR). ‘ ’ represents outliers.
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use of AS605240 was observed during the 2-week period of
the experiments. PI3K p110g inhibition attenuated protei-
nuria that was induced by ADR (Figure 7a). AS605240 also
decreased mRNA expression of type-I collagen and fibronec-
tin (Figure 7b), as well as fibrotic histological changes and
collagen deposition (Figure 7c). Nephrin (protein) and
podocalyxin (mRNA) expression were preserved in animals
treated with AS605240 (Figure 7d and e), suggesting that
in vivo inhibition of p110g protects against ADR-induced
podocyte injury.
To determine how p110g affects podocyte function, we
examined its role in podocyte injury in culture. p110g protein
expression was detected by immunoblotting, and AS605240
(1mmol/l) reduced basal Akt activity in cultured podocytes,
suggesting that the p110g isoform is indeed expressed
and contributes to downstream Akt activity in podocytes
(Figure 8a). In comparison, TGF-b-stimulated Smad activity
was not affected by the p110g inhibitor (not shown). ADR
treatment (20mg/ml, 16 h) significantly increased p110g
mRNA expression in cultured podocytes (Figure 8b). ADR
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Figure 6 |Phosphatidylinositol-3-kinase c expression is increased in adriamycin (ADR) nephropathy. (a) Akt phosphorylation is
increased in ADR nephropathy. Tissue sections were stained with an antibody to pAkt (Ser 473). Staining is present in both nuclear and
cytoplasmic patterns in ADR kidney, with particularly intense staining in glomerular nuclei. Bar¼ 25 mm. (b) Quantitative PCR of mRNA
indicates that only the 110g subunit shows increased expression in ADR mouse kidneys (N¼ 4, *Po0.05 compared with the corresponding
control). p110d was not detected. (c) Immunofluorescence microscopy for p110g and nephrin shows colocalization in a podocyte pattern.
Representative images (control, day 3 and day 6 after ADR administration) of p110g (left panels, Alexa-488 detection), nephrin (middle
panels, NorthernLight detection), and merged images with nuclear co-staining (40,6-diamidino-2-phenylindole (DAPI), right panels) are
shown. 63 1.4 (oil) objective. Bar¼ 20mm.
Figure 7 | Specific inhibition of p110c prevents adriamycin (ADR)-induced nephropathy. ADR nephropathy was induced in the
presence or absence of treatment with AS605240 (AS), a biochemical inhibitor of p110g activity (30mg/kg, intraperitoneally, 1 day
before ADR administration and every other day thereafter). (a) Twenty-four hour urine collection was performed on day 14 after ADR
administration, just before killing the mice. Albumin excretion was significantly ameliorated by AS treatment (N shown in parentheses under
each condition. Po0.001 by one-way analysis of variance (ANOVA), *Po0.001 compared with control, wP¼ 0.011 compared with ADR).
(b) Type-I collagen or fibronectin mRNA expression induced by ADR, determined by quantitative PCR (qPCR), was prevented by AS
treatment (day 14, N shown in parentheses under each condition. COL1A2: P¼ 0.02 by one-way ANOVA, *P¼ 0.014 compared with control,
wP¼ 0.035 compared with ADR; fibronectin: P¼ 0.04 by one-way ANOVA, *P¼ 0.029 compared with control, wP¼ 0.027 compared with
ADR). (c) Sections were stained with PAS ( 10 objective, top panels and  40 objective, middle panels) or trichrome ( 40 objective,
bottom panels) staining. Bar¼ 100 mm ( 10 objective) and 25 mm ( 40 objective). AS ameliorated glomerulosclerosis, tubular atrophy,
and interstitial fibrosis (day 14). (d) Glomerular nephrin, detected by immunofluorescence microscopy, is markedly decreased in ADR-treated
mice, but is preserved when those mice are also treated with AS. 40 1.4 (oil) objective, Bar¼ 20mm. (e) Podocalyxin mRNA expression,
determined by qPCR, is markedly decreased with ADR treatment but is protected with AS (day 14, N shown in parentheses under each
condition. P¼ 0.025 by one-way ANOVA, *P¼ 0.016 compared with control, wP¼ 0.008 compared with ADR). ‘ ’ represents outliers.
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treatment induced podocyte apoptosis, as detected by
expression of cleaved caspase 3 product (Figure 8c) and
staining with an early apoptosis marker, cytoDEATH (Figure
8d, upper panels), and disorganization of the cytoskeletal
stress fiber pattern (Figure 8e) that is seen normally in
differentiated podocytes.26 These podocyte changes were
prevented by pretreatment with AS605240, supporting a role
for PI3K p110g in podocyte injury. In contrast, a TGF-b
receptor kinase inhibitor, SB431542, did not affect podocyte
apoptosis nor cytoskeletal disorganization by ADR. Further,
ADR induced cleaved caspase 3 products even in a Smad3/
podocyte (Figure 8c, bottom panels). Together, these data
indicate that ADR-stimulated podocyte damage is mediated
by PI3K p110g, but independent of TGF-b in the time frame
that we studied.
Distinct roles of PI3K p110c and TGF-b and in kidney fibrosis
We next addressed a possible hierarchy between p110g and
TGF-b signaling in our model. The increased pAkt activity
that we observed in ADR-treated mouse glomeruli (Figure 6)
was not affected by sTbRII-Fc (Figure 9a). Conversely, ADR-
stimulated TGF-b1 mRNA expression in mouse kidneys was
prevented by treatment with the p110g inhibitor (Figure 9b).
These results suggest that p110g activation and podocyte
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Figure 8 |p110c expression and function in cultured podocytes. (a) Expression and activity of the p110g isoform in podocytes.
The protein expression was detected by western blot analysis. Akt phosphorylation, but not expression, is decreased by treatment
with AS605240 (1 mmol/l), confirming the efficacy of the inhibitor. (b) Induction of p110g mRNA in podocytes treated with adriamycin
(ADR). Podocytes were cultured with and without ADR (20 mg/ml, 16 h) before RNA was harvested for quantitative PCR (N¼ 3, each
reaction was performed in triplicate, *Po0.05 compared with control). (c) Induction by ADR of cleaved caspase 3 (Cl. Cas3) products
in podocytes does not require the TGF-b/Smad pathway. Podocytes, either wild type or Smad3 /, were treated with inhibitors
(AS605240; AS, 1 mmol/l, SB431542; SB, 5 mmol/l) or vehicle for 1 h, followed by ADR treatment (20mg/ml, 6 h), and Cl. Cas3 was detected
by immunoblot. Representative blots are shown from three separate experiments. (d, e) ADR induces podocyte apoptosis and
cytoskeletal dysorganization in a p110g-dependent manner. Cells were cultured with ADR (20 mg/ml) for 6 h following 1-h pretreatment
with either AS605240 (AS, 1 mmol/l) or SB431542 (SB, 5 mmol/l), and then fixed and stained with M30 CytoDEATH, a marker for early
apoptosis along with nuclear 40 ,6-diamidino-2-phenylindole staining (d) or with rhodamine-phalloidin to demonstrate actin stress
fibers (e). Apoptosis marker expression and stress fiber disorganization were prevented by AS, but not by SB. 63 1.4 (oil) objective,
bar¼ 10mm.
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injury precede the induction of TGF-b expression. In culture,
podocytes express little type-I collagen mRNA both basally
and in response to TGF-b1 (data not shown), and TGF-b1
treatment did not change p110g protein expression (Figure
9c). In the HKC line, the p110g-specific PI3K inhibitor did
not affect TGF-b induction of collagen mRNA expression
(Figure 9d), whereas a general PI3K inhibitor that blocks all
classes of PI3K including the ubiquitously expressed a and b
isoforms, LY294002, abrogated the collagen response, as we
have reported previously.9 Therefore, the PI3Kg inhibitor did
not ameliorate fibrosis by directly inhibiting glomerular
collagen expression, but rather by preventing glomerular
injury and suppressing subsequent production of a fibrogenic
cytokine TGF-b.
DISCUSSION
In progressive renal failure, a final common pathway
culminates in glomerulosclerosis and tubulointerstitial
fibrosis, irrespective of the nature of the original disease.
Understanding the molecular mechanisms that are involved
is important for developing specific, effective treatments.
Animal models of glomerulopathies have been used widely to
study signaling pathways involved in the pathogenesis of
renal fibrosis. Previous studies suggested that injury to
podocytes, essential elements in maintaining glomerular
filtration barrier integrity, is the initiating cause of many
genetic27 and acquired—both primary and secondary3,28,29—
renal diseases. In the present paper, we describe a modified
version of a previously established rodent model of ADR
nephropathy17,30 and use it to dissect renal fibrotic mechan-
isms. In 129x1/SvJ mice, proteinuria, chemical indices of
nephrotic syndrome, and glomerular and tubulointerstitial
accumulation of type-I collagen and fibronectin occur
sequentially after ADR administration. These changes are
similar in nature and order to those of human focal
segmental glomerular sclerosis. In contrast, preliminary
experiments with Balb/c mice (not shown) yielded a more
diffuse and aggressive pattern of injury. We therefore
propose that the present model offers a pattern of injury
and response more representative of human, progressive
glomerulosclerosis.
In evaluating non-canonical TGF-b signaling that we
previously described in vitro, we found increased Akt activity
in both Balb/c and 129x1/SvJ kidneys after ADR treatment.
We were surprised that only the g isoform of PI3K showed
increased expression. PI3K p110g is highly enriched in
leukocytes but also is expressed in cardiomyocytes, endothe-
lial cells, pancreatic islets, and smooth muscle cells.24,31–33
The likely source of this isoform in our model is the
podocyte, as p110g colocalizes with nephrin in mouse
glomeruli, and cultured podocytes express this isoform.
Intact actin cytoskeletal structure is essential for the
maintenance of effective foot-processes morphology and
normal podocyte function,2 and PI3K-dependent Akt activity
has been shown to regulate this structure.34 As we previously
showed that a pan-PI3K inhibitor, LY294002, blocked TGF-
b1 induction of type-I collagen expression in cultured renal
cells,9 we evaluated the effect of LY294002 in vivo. Our results
were inconclusive; some mice that survived showed histolo-
gical amelioration of ADR nephropathy, whereas others died
from possible toxicity or even from exacerbation of the
disease. It is noteworthy that treatment with LY294002 alone
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Figure 9 |Distinct roles for transforming growth factor (TGF)-b and p110c in renal cell collagen expression. (a) pAkt activity in
adriamycin (ADR) mouse glomeruli. ADR mouse kidney samples (day 14) were stained with an antibody to pAkt. Representative images are
shown. pAkt activity was present in ADR-treated glomeruli with or without soluble TGF-b type-II receptor-Fc treatment, suggesting that
pAkt activity is independent of TGF-b production. 63 1.4 (oil) objective, bar¼ 10mm. (b) Expression of TGF-b1 mRNA in ADR nephropathy.
TGF-b1 mRNA in mouse kidneys harvested 14 days after ADR administration was quantified by quantitative PCR (qPCR). Expression was
increased by ADR treatment, an effect that was prevented in mice treated with AS605240 (AS; N shown in parentheses under each
condition. P¼ 0.038 by one-way analysis of variance, *P¼ 0.02 compared with control, wP¼ 0.025 compared with ADR). (c) Effects of TGF-b
on podocyte p110g expression. Cultured podocytes were treated with TGF-b1 (1.0 ng/ml, 24 h) or vehicle and p110g protein levels were
evaluated by immunoblotting. p110g expression was not affected by TGF-b. Representative blots are shown from three separate
experiments. (d) Effect of AS on TGF-b-stimulated collagen mRNA expression. Podocytes did not produce type-I collagen in response to
TGF-b1. Accordingly, the renal tubular cell line, HKC, was treated with TGF-b1 (1.0 ng/ml, 24 h) in the presence or absence of inhibitors and
COL1A1 mRNA was determined by qPCR. AS did not prevent the collagen response, which was decreased by the pan-PI3K antagonist,
LY294002 (LY, 20mmol/l). Representative results from one of three separate experiments, each performed in triplicate, are shown.
‘ ’ represents outliers.
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consistently increased urine albumin compared with negative
control mice (data not shown). On the other hand, specific
blockade of the p110g isoform of PI3K with AS605240
decreased proteinuria and fibrosis in ADR-treated mice,
without affecting control mice. Further, inhibiting p110g
activity in cultured podocytes using AS605240 decreased
ADR-stimulated cytoskeletal disorganization and induction
of apoptotic markers in cultured cells. Together, these data
suggest that p110g has a significant role in mediating
podocyte injury at the initiation of the disease process. In
contrast, AS605240 did not inhibit TGF-b-stimulated
collagen expression in cultured cells, indicating that p110g
does not directly mediate TGF-b-stimulated fibrogenesis.
Further, ADR-increased renal expression of TGF-b was
partially blocked by the p110g inhibitor in vivo, suggesting
that p110g activity precedes TGF-b expression and conse-
quent collagen production. Consistent with this hypothesis,
sTbRII-Fc did not prevent either glomerular pAkt activity
induced by PI3K p110g in vivo or ADR-induced podocyte
damage in vitro.
These findings suggest that PI3K p110g is a novel
therapeutic target mediating podocyte injury. Although the a
and b isoforms of PI3K are ubiquitously expressed and the
most well studied, they are activated primarily by a receptor
tyrosine kinase. The g isoform, which is relatively restricted to
hematopoietic cells, is uniquely activated by G protein–coupled
receptor agonists. Owing to its tissue distribution, specific roles
for the g isoforms were preferentially evaluated in inflamma-
tory and/or autoimmune disease models such as asthma and
systemic lupus erythematosus, and were determined to have a
role in immune cell function.25,35,36 Given the potential role of
p110g in inflammation, we cannot rule out the possibility that
p110g inhibition ameliorates disease progression in part
through an anti-inflammatory mechanism. Nevertheless, our
data are consistent with a model in which PI3K P110g has an
important role specifically in podocyte injury.
TGF-b is generally accepted as a central mediator in
kidney fibrosis (reviewed in Schnaper et al.7 and references
therein). Its fibrogenic properties are supported by a
transgenic mouse model of TGF-b overexpression37 and by
subsequent studies in several animal models of kidney
fibrosis. Our results show that extracellular matrix expression
in ADR mouse kidney was mediated by TGF-b, as indicated
by increased expression of TGF-b, Smad3 phosphorylation,
nuclear translocation of Smad3, and amelioration of disease
manifestations by sTbRII-Fc. As p110g activity occurs before
TGF-b expression, prevention of fibrotic marker expression
in ADR-treated mouse kidneys by AS605240 likely represents
blockade of the events initiating the disease rather than direct
interference with a TGF-b-mediated mechanism. Conversely,
sTbRII-Fc decreased fibrosis but did not prevent proteinuria.
Together, our results define distinct and sequential roles of
p110g and TGF-b, the former as an initial stress response to
ADR leading to podocyte injury, proteinuria, and TGF-b
expression, and the latter contributing to subsequent
extracellular matrix accumulation. Other isoforms of PI3K,
probably a and/or b, likely interfere with signaling down-
stream from TGF-b, as we previously showed in vitro.9 The
proposed signaling cascade involving PI3K and TGF-b is
depicted as a diagram (Figure 10). The sequence of events
that we propose is supported by the following observations:
(1) proteinuria precedes fibrosis; (2) ADR-stimulated
changes in podocyte function that are consistent with causal
events in proteinuria are blocked by AS605240; (3) p110g
antagonism prevents both proteinuria and fibrosis; and (4)
sTbRII-Fc ameliorates fibrosis but not proteinuria.
One of the main advantages of our model in 129x1/SvJ is
the nature of the histological lesion, which differs from the
more aggressive tissue damage observed in Balb/c mice
(5,17,19,30 and our unpublished results). Thus, results from the
current model may reflect a series of events from an earlier
stage of the disease than those observed in Balb/c. We note
that the lesion in this model is not purely glomerular, and
dilated tubules and tubulointerstitial fibrosis are also prom-
inent. However, the initial podocyte damage and sustained
proteinuria suggest that the model represents a primary
glomerular process that, in an accelerated manner, invokes
the same mechanisms of disease progression that are
observed in human focal segmental glomerular sclerosis.
Further understanding of the molecular mechanisms under-
lying progression of chronic kidney disease is crucial for
successful treatment. Additional studies will help us apply
experimental evidence to patient therapy.
Adriamycin
Podocyte
Podocyte injury
Proteinuria
Fibrotic cytokines
(TGF-β)
ECM accumulation
and
glomerular fibrogenesis
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(PI3Kα/β)
TβR II Fc
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(PI3Kγ)
p110γ induction
Figure 10 |Putative mechanisms by which
phosphatidylinositol-3-kinase (PI3K)c and transforming
growth factor (TGF)-b exert distinct effects in kidney fibrosis.
Adriamycin causes podocyte injury by a mechanism that is
inhibited by AS605240 (AS), indicating a role for PI3K p110g.
Subsequently, TGF-b-dependent fibrogenic activity is inhibited by
soluble TGF-b type-II receptor-Fc (sTbRII-Fc) or by LY294002 (LY),
but not by AS605240. These results indicate that initial podocyte
injury involves the action of p110g, whereas subsequent
fibrogenesis requires TGF-b and another non-g isoform of PI3K.
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MATERIALS AND METHODS
Animal model
Animal experiments were conducted in accordance with the
regulations set by the institutional committee for the care and use
of laboratory animals. Male 129x1/SvJ mice 6–8 weeks old weighing
24–26 g (Jackson Laboratory, Bar Harbor, ME) were fed a standard
laboratory diet and provided with water ad libitum. Disease was
induced by a single intravenous injection of ADR, 15mg/kg
(Research Product International, Mt Prospect, IL), in 0.9% saline.
Control mice received the same volume of saline. sTbRII-Fc, pro-
duced by H Lin,23 was injected intravenously (4mg/kg) a day before
ADR injection, followed by intraperitoneal injections (2mg/kg) twice
weekly thereafter for a total of five doses. A p110g-specific inhibitor,
AS605240 (EMD Chemicals, Gibbstown, NJ), was reconstituted in
dimethyl sulfoxide for stock solution and further diluted with 0.9%
saline before each injection. p110g inhibitor (30mg/kg) was admini-
stered intraperitoneally starting the day before ADR injection and
every other day thereafter. Before killing, 24-h urine samples were
collected in a metabolic cage. Blood samples were taken by cardiac
puncture after anesthesia. The kidneys were rapidly removed and
preserved in halves for later processing for protein, mRNA, histology,
and immunofluorescence studies.
Renal histopathology
Specimens were fixed in 10% neutral-buffered formalin, and
paraffin-embedded and sectioned (4mm thick) by Northwestern
University Mouse Histology and Phenotyping Laboratory. Periodic
acid–Schiff and Masson’s trichrome staining (Accustain, Sigma,
St Louis, MO) were performed according to the manufacturer’s
instruction. The stained sections were coded and examined by two
independent observers who were blinded to the treatment groups.
The histological changes for segmental glomerulosclerosis, tubular
dilatation, protein cast deposition inside the tubules, and interstitial
fibrosis were evaluated semiquantitatively by a scoring system of 0–3,
where 0¼ no change; 1¼mild change; 2¼moderate; and 3¼ severe.
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded, 4-mm sections were prepared
and mounted on glass slides, deparaffinized, rehydrated, and then
subjected to antigen retrieval following the vendor’s instructions
(DAKO, Carpinteria, CA). The sections were incubated with 3% H2O2
to quench endogenous peroxidase activity. After treating with a
blocking solution (Power Block, BioGenex, San Ramon, CA), the
sections were incubated with primary antibody (DAKO) overnight.
The bound antibody was detected by peroxidase-conjugated secondary
antibody and visualized with DAB substrate (Invitrogen, Carlsbad,
CA), followed by hematoxylin counterstaining. For immunofluores-
cence microscopy, freshly frozen 1–2mm slices of kidney tissues were
fixed with 4% paraformaldehyde at 4 1C overnight. They were
embedded in 30% sucrose/1.5% agarose and 10-mm-thick cryosections
were prepared using Leica CM1850 Cryotome (Leica Microsystems,
Wetzlar, Germany), followed by standard immunostaining procedures.
Antibodies that were isotype-matched to the primary antibodies were
used as negative controls. Images were captured using an Axioscope
equipped with ultraviolet epi-illumination or Zeiss LSM 510 META
laser scanning confocal microscope (Zeiss, Thornwood, NY).
Determination of mouse urinary protein excretion and serum
biochemistry
Albuminuria was measured using an Albuwell ELISA kit (Exocell,
Philadelphia, PA) according to the manufacturer’s protocol. Mouse
serum was analyzed for albumin, cholesterol, creatinine, and blood
urea nitrogen by Charles River Laboratories (Wilmington, MA).
Evaluation of mRNA expression
Total RNA was extracted from tissue preserved with RNAlater using
the RNeasy mini kit with DNase (Qiagen, Valencia, CA) as instructed
by the manufacturer. A measure of 1 mg of RNA, quantified with the
Quant-it RiboGreen assay (Invitrogen), was reverse-transcribed with
the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA)
and subjected to quantitative PCR using the iQ SYBR Green
Supermix (Bio-Rad Laboratories) with the iCycler iQ real-time PCR
detection system (Bio-Rad Laboratories). Real-time data were
collected for 40 cycles of 95 1C, 10 s; 57 1C, 45 s; and 75 1C, 30 s.
Primers used are custom-synthesized by either Integrated DNA
Technology (Coralville, CA) or Invitrogen. Relative expression of the
gene of interest was estimated by the DDCt method using 18S or
b2-microglobulin as a reference gene. Samples were analyzed in triplic-
ate, and experiments were repeated at least three times. Detailed primer
information is attached as Table S1 in the Supplementary Data online.
In vitro studies
Cell culture and treatment. Mouse podocytes were kindly
provided by Dr E Bottinger38 and maintained as previously
described.26 Briefly, cells were propagated in a permissive condition
(33 1C) with RPMI1640 supplemented with 10% heat-inactivated
fetal bovine serum and interferon-g (20U/ml, Cell Sciences, Canton,
MA) on dishes coated with rat type-I collagen (BD Biosciences,
Bedford, MA). Differentiation was induced in the absence of
interferon-g at 37 1C for at least 2 weeks. The human renal tubular
epithelial cell line HKC, generously gifted by Dr L Racusen,39 was
cultured in Dulbecco’s modified Eagle’s medium/F-12 supplemented
with 10% fetal bovine serum, penicillin/streptomycin, amphotericin
B, HEPES buffer, and glutamine.
Preparation of cell lysate and western blot analysis. Cells were
lysed on ice in RIPA buffer (50mmol/l Tris/HCl, pH 7.5, 150mmol/l
NaCl, 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS) containing
protease and phosphatase inhibitor cocktails (Sigma). Protein samples
were subjected to immunoblotting, and immunoreactive bands were
visualized using a chemiluminescence reagent according to the manu-
facturer’s protocol (Santa Cruz Biotechnology, Santa Cruz, CA).
Immunocytochemistry
Cells were plated on gelatin-coated glass coverslips and immuno-
stained with a standard protocol and examined under a Zeiss LSM
510 meta confocal microscope as previously described.40 Early
apoptosis was detected by M30 CytoDEATH (Roche Applied
Bioscience, Indianapolis, IN).
Antibodies and reagents
The following primary antibodies were purchased: nephrin (R&D
systems, Minneapolis, MN), pSmad3 (Ser 425) and p110g (Abcam,
Cambridge, MA), pAkt (Ser 473) and Akt (Cell Signaling, Danvers,
MA), type-I collagen (Fitzgerald, Concord, MA), Rhodamine-
Phalloidin (Cytoskeleton, Denver CO), and secondary antibodies;
NorthernLight-conjugated secondary antibodies (R&D systems),
Alexa-conjuaged secondary antibodies (Invitrogen), peroxidase-
conjuaged secondary antibodies (Abcam or Invitrogen).
TGF-b1 (R&D systems) was reconstituted as previously described
and used at a final concentration of 1.0 ng/ml.8 SB431542 and
AS605240 were purchased from EMD Chemicals and reconstituted in
dimethyl sulfoxide.
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Statistical analysis
Statistical analyses were performed using GraphPad Prism version
4.0. for Macintosh (GraphPad Software, San Diego, CA) for Student’s
t test or one- or two-way analysis of variance followed by Fisher’s
post-hoc analysis. Po0.05 was considered significant.
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